190 related articles for article (PubMed ID: 37460153)
1. Localization of unlabeled bepirovirsen antisense oligonucleotide in murine tissues using in situ hybridization and CARS imaging.
Spencer-Dene B; Mukherjee P; Alex A; Bera K; Tseng WJ; Shi J; Chaney EJ; Spillman DR; Marjanovic M; Miranda E; Boppart SA; Hood SR
RNA; 2023 Oct; 29(10):1575-1590. PubMed ID: 37460153
[TBL] [Abstract][Full Text] [Related]
2. Differential Uptake of Antisense Oligonucleotides in Mouse Hepatocytes and Macrophages Revealed by Simultaneous Two-Photon Excited Fluorescence and Coherent Raman Imaging.
Mukherjee P; Aksamitiene E; Alex A; Shi J; Bera K; Zhang C; Spillman DR; Marjanovic M; Fazio M; Seth PP; Frazier K; Hood SR; Boppart SA
Nucleic Acid Ther; 2022 Jun; 32(3):163-176. PubMed ID: 34797690
[TBL] [Abstract][Full Text] [Related]
3. Co-Administration of an Excipient Oligonucleotide Helps Delineate Pathways of Productive and Nonproductive Uptake of Phosphorothioate Antisense Oligonucleotides in the Liver.
Donner AJ; Wancewicz EV; Murray HM; Greenlee S; Post N; Bell M; Lima WF; Swayze EE; Seth PP
Nucleic Acid Ther; 2017 Aug; 27(4):209-220. PubMed ID: 28448194
[TBL] [Abstract][Full Text] [Related]
4. Intracellular Absolute Quantification of Oligonucleotide Therapeutics by NanoSIMS.
Becquart C; Stulz R; Thomen A; Dost M; Najafinobar N; Dahlén A; Andersson S; Ewing AG; Kurczy ME
Anal Chem; 2022 Jul; 94(29):10549-10556. PubMed ID: 35830231
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the effects of chemically different linkers on hepatic accumulations, cell tropism and gene silencing ability of cholesterol-conjugated antisense oligonucleotides.
Wada S; Yasuhara H; Wada F; Sawamura M; Waki R; Yamamoto T; Harada-Shiba M; Obika S
J Control Release; 2016 Mar; 226():57-65. PubMed ID: 26855051
[TBL] [Abstract][Full Text] [Related]
6. High-sensitivity quantification of antisense oligonucleotides for pharmacokinetic characterization.
Mahajan S; Zhao H; Kovacina K; Lachacz E; Hoxha S; Chan J; Liang M
Bioanalysis; 2022 May; 14(9):603-613. PubMed ID: 35578971
[TBL] [Abstract][Full Text] [Related]
7. Characterization of target mRNA reduction through in situ RNA hybridization in multiple organ systems following systemic antisense treatment in animals.
Hung G; Xiao X; Peralta R; Bhattacharjee G; Murray S; Norris D; Guo S; Monia BP
Nucleic Acid Ther; 2013 Dec; 23(6):369-78. PubMed ID: 24161045
[TBL] [Abstract][Full Text] [Related]
8. Weakly Supervised Identification and Localization of Drug Fingerprints Based on Label-Free Hyperspectral CARS Microscopy.
Shi J; Bera K; Mukherjee P; Alex A; Chaney EJ; Spencer-Dene B; Majer J; Marjanovic M; Spillman DR; Hood SR; Boppart SA
Anal Chem; 2023 Jul; 95(29):10957-10965. PubMed ID: 37450658
[TBL] [Abstract][Full Text] [Related]
9. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice.
Prakash TP; Graham MJ; Yu J; Carty R; Low A; Chappell A; Schmidt K; Zhao C; Aghajan M; Murray HF; Riney S; Booten SL; Murray SF; Gaus H; Crosby J; Lima WF; Guo S; Monia BP; Swayze EE; Seth PP
Nucleic Acids Res; 2014 Jul; 42(13):8796-807. PubMed ID: 24992960
[TBL] [Abstract][Full Text] [Related]
10. Comparative Characterization of Hepatic Distribution and mRNA Reduction of Antisense Oligonucleotides Conjugated with Triantennary N-Acetyl Galactosamine and Lipophilic Ligands Targeting Apolipoprotein B.
Watanabe A; Nakajima M; Kasuya T; Onishi R; Kitade N; Mayumi K; Ikehara T; Kugimiya A
J Pharmacol Exp Ther; 2016 May; 357(2):320-30. PubMed ID: 26907624
[TBL] [Abstract][Full Text] [Related]
11. A single-cell map of antisense oligonucleotide activity in the brain.
Mortberg MA; Gentile JE; Nadaf NM; Vanderburg C; Simmons S; Dubinsky D; Slamin A; Maldonado S; Petersen CL; Jones N; Kordasiewicz HB; Zhao HT; Vallabh SM; Minikel EV
Nucleic Acids Res; 2023 Aug; 51(14):7109-7124. PubMed ID: 37188501
[TBL] [Abstract][Full Text] [Related]
12. Fast vibrational imaging of single cells and tissues by stimulated Raman scattering microscopy.
Zhang D; Wang P; Slipchenko MN; Cheng JX
Acc Chem Res; 2014 Aug; 47(8):2282-90. PubMed ID: 24871269
[TBL] [Abstract][Full Text] [Related]
13. Evidence for a specific intracellular localization of an antisense oligonucleotide in k562 cells.
Vasconcelos MH; Maia LF; Sousa C; Beleza SS; Guimarães JE
J Pharmacol Sci; 2005 Sep; 99(1):105-8. PubMed ID: 16141637
[TBL] [Abstract][Full Text] [Related]
14. Cholesterol-GalNAc Dual Conjugation Strategy for Reducing Renal Distribution of Antisense Oligonucleotides.
Wada F; Yamamoto T; Ueda T; Sawamura M; Wada S; Harada-Shiba M; Obika S
Nucleic Acid Ther; 2018 Feb; 28(1):50-57. PubMed ID: 29360004
[TBL] [Abstract][Full Text] [Related]
15. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin.
Zellweger T; Miyake H; July LV; Akbari M; Kiyama S; Gleave ME
Neoplasia; 2001; 3(4):360-7. PubMed ID: 11571636
[TBL] [Abstract][Full Text] [Related]
16. Disarmed anthrax toxin delivers antisense oligonucleotides and siRNA with high efficiency and low toxicity.
Dyer PDR; Shepherd TR; Gollings AS; Shorter SA; Gorringe-Pattrick MAM; Tang CK; Cattoz BN; Baillie L; Griffiths PC; Richardson SCW
J Control Release; 2015 Dec; 220(Pt A):316-328. PubMed ID: 26546271
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and Pharmacodynamic Investigations of ION-353382, a Model Antisense Oligonucleotide: Using Alpha-2-Macroglobulin and Murinoglobulin Double-Knockout Mice.
Shemesh CS; Yu RZ; Gaus HJ; Seth PP; Swayze EE; Bennett FC; Geary RS; Henry SP; Wang Y
Nucleic Acid Ther; 2016 Aug; 26(4):223-35. PubMed ID: 27031383
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the Activity and Distribution of a 2'-O-Methoxyethyl-Modified Antisense Oligonucleotide in Models of Acute and Chronic Kidney Disease.
Donner AJ; Bell TA; Greenlee S; Graham MJ; Crooke RM
Nucleic Acid Ther; 2018 Oct; 28(5):297-306. PubMed ID: 30133341
[TBL] [Abstract][Full Text] [Related]
19. Absorption, Distribution, Metabolism, and Excretion of US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs.
Migliorati JM; Liu S; Liu A; Gogate A; Nair S; Bahal R; Rasmussen TP; Manautou JE; Zhong XB
Drug Metab Dispos; 2022 Jun; 50(6):888-897. PubMed ID: 35221287
[TBL] [Abstract][Full Text] [Related]
20. Characterizing the effect of GalNAc and phosphorothioate backbone on binding of antisense oligonucleotides to the asialoglycoprotein receptor.
Schmidt K; Prakash TP; Donner AJ; Kinberger GA; Gaus HJ; Low A; Østergaard ME; Bell M; Swayze EE; Seth PP
Nucleic Acids Res; 2017 Mar; 45(5):2294-2306. PubMed ID: 28158620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
